Ashvattha Therapeutics Announces First Patient Dosed via Subcutaneous Administration of Anti-Angiogenic Therapeutic D-4517.2 for Wet AMD and DME in Phase 2 Chronic Dosing Study

Open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME) Favorable safety and tolerability results from Phase 1 and Phase 2 single dose studies of D-4517.2 support initiation of chronic dosing study Preliminary data expected in 1H 2024   … Read more